-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Upgrades Cellectar Biosciences to Buy, Announces $10 Price Target

Benzinga·03/10/2026 13:20:30
Listen to the news
Maxim Group analyst Jason McCarthy upgrades Cellectar Biosciences (NASDAQ:CLRB) from Hold to Buy and announces $10 price target.